Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katie Lewis

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
European Thyroid Journal|January 8, 2024
Real-world clinical profile, RET mutation testing, treatments, and PROs for MTC in EuropeGrace Segall, Ravinder Singh, Min-Hua Jen, et al.
Breast (Edinburgh, Scotland)|November 11, 2022
Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and IsraelReshma Mahtani, Alexander Niyazov, Bhakti Arondekar, et al.
Cancers|November 11, 2022
<i>BRCA1/2</i> Mutation Testing in Patients with HER2-Negative Advanced Breast Cancer: Real-World Data from the United States, Europe, and IsraelReshma Mahtani, Alexander Niyazov, Bhakti Arondekar, et al.
Advances in Therapy|November 5, 2022
Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and IsraelReshma Mahtani, Alexander Niyazov, Katie Lewis, et al.
BMC Medical Genomics|May 10, 2018
Clinical providers' experiences with returning results from genomic sequencing: an interview studyJulia Wynn, Katie Lewis, Laura M Amendola, et al.
European Journal of Human Genetics : EJHG|November 28, 2013
Research participants' attitudes towards the confidentiality of genomic sequence informationLeila Jamal, Julie C Sapp, Katie Lewis, et al.
Public Health Research (Southampton, England)|March 30, 2026
The NIHR Public Health Research Review Programme (2019-2025)Elizabeth Goyder, Andrew Booth, Katie Lewis, et al.
Future Oncology (London, England)|June 25, 2026
Real-world treatment landscape and disease burden of myelofibrosis in Taiwan, South Korea, Japan, and CanadaKingo Kanda, Yusuke Yasutomi, Katie Lewis, et al.
Breast (Edinburgh, Scotland)|February 20, 2026
Real-world treatment patterns and sequencing in patients with advanced / metastatic HR+/HER2- breast cancer in Europe and the United StatesReshma Mahtani, Beata Korytowsky, Chloe Grace Rose, et al.
BMC Cancer|September 7, 2020
Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2- advanced breast cancer in five European countriesAlison Davie, Gebra Cuyun Carter, Alex Rider, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
European Thyroid Journal|January 8, 2024
Real-world clinical profile, RET mutation testing, treatments, and PROs for MTC in EuropeGrace Segall, Ravinder Singh, Min-Hua Jen, et al.
Breast (Edinburgh, Scotland)|November 11, 2022
Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and IsraelReshma Mahtani, Alexander Niyazov, Bhakti Arondekar, et al.
Cancers|November 11, 2022
<i>BRCA1/2</i> Mutation Testing in Patients with HER2-Negative Advanced Breast Cancer: Real-World Data from the United States, Europe, and IsraelReshma Mahtani, Alexander Niyazov, Bhakti Arondekar, et al.
Advances in Therapy|November 5, 2022
Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and IsraelReshma Mahtani, Alexander Niyazov, Katie Lewis, et al.
BMC Medical Genomics|May 10, 2018
Clinical providers' experiences with returning results from genomic sequencing: an interview studyJulia Wynn, Katie Lewis, Laura M Amendola, et al.
European Journal of Human Genetics : EJHG|November 28, 2013
Research participants' attitudes towards the confidentiality of genomic sequence informationLeila Jamal, Julie C Sapp, Katie Lewis, et al.
Public Health Research (Southampton, England)|March 30, 2026
The NIHR Public Health Research Review Programme (2019-2025)Elizabeth Goyder, Andrew Booth, Katie Lewis, et al.
Future Oncology (London, England)|June 25, 2026
Real-world treatment landscape and disease burden of myelofibrosis in Taiwan, South Korea, Japan, and CanadaKingo Kanda, Yusuke Yasutomi, Katie Lewis, et al.
Breast (Edinburgh, Scotland)|February 20, 2026
Real-world treatment patterns and sequencing in patients with advanced / metastatic HR+/HER2- breast cancer in Europe and the United StatesReshma Mahtani, Beata Korytowsky, Chloe Grace Rose, et al.
BMC Cancer|September 7, 2020
Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2- advanced breast cancer in five European countriesAlison Davie, Gebra Cuyun Carter, Alex Rider, et al.
Pageof 4